Fda accepts dupixent® (dupilumab) for priority review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

Tarrytown, n.y. and paris , feb. 10, 2022 /prnewswire/ -- if approved, dupixent will be the first biologic medicine available in the u.s. to treat uncontrolled moderate-to-severe atopic dermatitis for these young children regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that the u.s. food and drug administration (fda) has accepted for priority review the supplemental biologics license application (sbla) for dupixent® (dupilumab) as an add-on maintenance treatment for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
REGN Ratings Summary
REGN Quant Ranking